TY - JOUR
T1 - Immediate pain alleviation in oral mucositis and other oral ulcerative diseases through photobiomodulation therapy
T2 - the preemptive treatment concept
AU - Elad, Sharon
AU - Keegan, Rebeca
AU - Fregnani, Eduardo Rodrigues
AU - Gavish, Lilach
AU - Ottaviani, Giulia
AU - Arany, Praveen
AU - Zadik, Yehuda
N1 - Publisher Copyright:
© 2024 Quintessenz Verlags-GmbH. All rights reserved.
PY - 2024/6/1
Y1 - 2024/6/1
N2 - Objective: Photobiomodulation therapy is recommended by multiple international societies for managing oral mucositis. These recommendations are based on extensive evidence. However, the search for an optimal photobiomodulation protocol continues. This mapping review focuses on a novel aspect of photobiomodulation therapy which is the immediate effect on pain levels associated with oral ulcerative conditions. Data sources: This literature review systematically compiles and evaluates the evidence about oral mucositis, alongside other oral ulcerative conditions, as the protocols that achieved pain relief for these oral conditions may have potential applicability to oral mucositis management. The scientific database used was PubMed. Conclusion: Whereas most of the randomized controlled trials about photobiomodulation therapy for oral mucositis and other ulcerative oral diseases reported delayed pain relief, certain photobiomodulation therapy protocols reported immediate pain relief. The results of this review highlight the concept of preemptive photobiomodulation therapy, in which photobiomodulation therapy is delivered early in the development of oral mucositis throughout the oncotherapy and may achieve immediate pain relief consistently in most of the patients and close to a negligible pain level. Photobiomodulation therapy, as a powerful nonpharmacologic tool for immediate pain relief, has a great beneficial value in patients suffering from oral mucositis and other painful oral ulcerative diseases such as recurrent aphthous stomatitis and chronic graft-versus-host disease.
AB - Objective: Photobiomodulation therapy is recommended by multiple international societies for managing oral mucositis. These recommendations are based on extensive evidence. However, the search for an optimal photobiomodulation protocol continues. This mapping review focuses on a novel aspect of photobiomodulation therapy which is the immediate effect on pain levels associated with oral ulcerative conditions. Data sources: This literature review systematically compiles and evaluates the evidence about oral mucositis, alongside other oral ulcerative conditions, as the protocols that achieved pain relief for these oral conditions may have potential applicability to oral mucositis management. The scientific database used was PubMed. Conclusion: Whereas most of the randomized controlled trials about photobiomodulation therapy for oral mucositis and other ulcerative oral diseases reported delayed pain relief, certain photobiomodulation therapy protocols reported immediate pain relief. The results of this review highlight the concept of preemptive photobiomodulation therapy, in which photobiomodulation therapy is delivered early in the development of oral mucositis throughout the oncotherapy and may achieve immediate pain relief consistently in most of the patients and close to a negligible pain level. Photobiomodulation therapy, as a powerful nonpharmacologic tool for immediate pain relief, has a great beneficial value in patients suffering from oral mucositis and other painful oral ulcerative diseases such as recurrent aphthous stomatitis and chronic graft-versus-host disease.
KW - aphthous stomatitis
KW - cancer
KW - graft vs host disease
KW - laser
KW - oral mucositis
KW - pain relief
KW - photobiomodulation
UR - http://www.scopus.com/inward/record.url?scp=85197542604&partnerID=8YFLogxK
U2 - 10.3290/j.qi.b5213529
DO - 10.3290/j.qi.b5213529
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38619258
AN - SCOPUS:85197542604
SN - 0033-6572
VL - 55
SP - 482
EP - 493
JO - Quintessence International
JF - Quintessence International
IS - 6
ER -